In new deal, AstraZeneca places small bet on ' critical but challenging ' target

In new deal, AstraZeneca places small bet on 'critical but challenging' target AstraZeneca has its eyes on NRF2 as a target for inflammatory and respiratory diseases, and it’s handing out $2 million in cash to pluck a preclinical candidate from a drug discovery shop. It’s so early that C4X…#readingendpoints #astrazeneca #discoveryshop #critical #challenging #target #discovery #drugdiscovery #endpoints #bet
Source: Reuters: Health - Category: Consumer Health News Source Type: news